Location History:
- Cedex, FR (1999)
- Nantes, Cedex, FR (1999)
- Nantes, FR (1998 - 2009)
Company Filing History:
4 out of 1,743 
1 out of 141 
Years Active: 1998-2009
Title: Yannick Guilloux: Innovator in Antitumoral Immunotherapy
Introduction
Yannick Guilloux is a prominent inventor based in Nantes, France. He has made significant contributions to the field of immunotherapy, particularly in the development of peptides for antitumoral applications. With a total of 4 patents, his work has the potential to impact cancer treatment significantly.
Latest Patents
Guilloux's latest patents include innovative approaches to antitumoral immunotherapy. One of his notable inventions involves peptides derived from the protein MMP-2, which form T cell epitopes when presented by MHC Class I molecules. This technology is aimed at enhancing anti-tumor therapy using these peptides. Additionally, he has developed methods for determining the expression of NAG tumor rejection antigen. This includes new tumor rejection antigen precursors and the nucleic acid molecules that code for them, referred to as NAG coding molecules. His patents describe various diagnostic and therapeutic uses of these coding sequences and tumor rejection antigen precursor molecules.
Career Highlights
Throughout his career, Yannick Guilloux has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and the Université de Nantes. His research has focused on advancing the understanding and treatment of tumors through innovative peptide therapies.
Collaborations
Guilloux has collaborated with notable colleagues, including Francine Jotereau and Thierry R Boon-Falleur. These partnerships have contributed to the development of his groundbreaking research and patents.
Conclusion
Yannick Guilloux stands out as an influential inventor in the field of antitumoral immunotherapy. His innovative patents and collaborations reflect his commitment to advancing cancer treatment through scientific research.